Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Nature Methods|September 3, 2024
Mapping cellular interactions from spatially resolved transcriptomics dataJames Zhu, Yunguan Wang, Woo Yong Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
Practical Radiation Oncology|July 17, 2024
Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice GuideAndrew B Barbour, Rituraj Upadhyay, August C Anderson, et al.
JAMA Oncology|March 14, 2024
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical TrialMark K Buyyounouski, Stephanie L Pugh, Ronald C Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 4, 2025
Efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the KidneyMuhammad Ali, Rohann J M Correa, David Pryor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2021
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell CarcinomaRaquibul Hannan, Osama Mohamad, Alberto Diaz de Leon, et al.
European Urology|March 1, 2026
KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic ModelChad Tang, Aaron Seo, Alexander D Sherry, et al.
Cancer Discovery|June 10, 2018
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory FactorsTao Wang, Rong Lu, Payal Kapur, et al.
Pageof 11